DSGN at a glance
Design Therapeutics, Inc. (DSGN, SEC CIK 1807120) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as June 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Design Therapeutics, Inc. (DSGN) reported revenue of $0 and a net loss of $69.8 million. Diluted EPS was -$1.22.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Design Therapeutics, Inc. (DSGN) shares worth $128.0 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 24 funds
- $128.0M · −3 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added trade-policy risk: 2025 tariffs and potential sanctions threaten foreign API supplies, increasing development costs and disrupting clinical timelines
- Most materially updated manufacturing risk: BIOSECURE Act restrictions could limit use of Chinese biotechnology suppliers after the mid-December 2026 designation list
- Regulatory risk: Loper Bright decision increases challenges to FDA rules and uncertainty around agency interpretations
- Near-term clinical risk: omaveloxolone availability may reduce FA trial enrollment for DT-216P2
- Financial risk: $208.6 million in cash, equivalents and investments funds operations over 12 months but not regulatory approval or commercialization
Management Discussion & Analysis
- Product revenue $0, unchanged YoY, no approved products or product sales
- Operating expenses $22.2M vs $19.3M YoY, research and development $16.9M vs $14.6M
- Best program: DM1 R&D $3.3M, up from $0; worst: FECD $1.6M vs $(1.1)M
- Cash, equivalents and investments $208.6M, down $11.2M from December 31, 2025
- Operating cash use $47.3M; ATM financing $37.1M, runway more than 12 months
AI summary of the DSGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release covers Design Therapeutics’ financial results for the three and nine months ended September 30, 2026
- Exhibit 99.1 contains the detailed financial results and management commentary for investor review
Item EX-99.1: Item EX-99.1
- Q3 2026 net loss $20.3M, or $0.32 per share, versus $17.0M and $0.30 in Q3 2025
- R&D spending rose to $16.9M from $14.6M, reflecting increased clinical development investment
Item 2.02: Results of Operations and Financial Condition
- Design Therapeutics reported financial results for Q2 and six months ended June 30, 2026
- Results detailed in Exhibit 99.1, the company’s accompanying earnings press release
Item EX-99.1: Item EX-99.1
- Q2 net loss $20.2M, or $0.32 per share, with R&D spending of $16.4M
- Cash and securities $207.4M at June 30, down from $219.8M at December 31
Item 5.07: Submission of Matters to a Vote of Security Holders
- Simeon George, M.D. elected Class II director through 2029 annual meeting
- Director vote: 29,205,208 for, 7,608,724 withheld, 13,264,883 broker non-votes
AI summaries of DSGN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DSGN
Don't miss the next DSGN filing
- Alerts as it files. A push when DSGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DSGN, by share count.
- Ask anything. An AI agent that reads every DSGN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Schmid John P. | A | Jun 9, 2026 | 30,000 | - |
| Berger Heather A. | A | Jun 9, 2026 | 30,000 | - |
| Gover Justin D. | A | Jun 9, 2026 | 30,000 | - |
| LAPPE RODNEY W | A | Jun 9, 2026 | 30,000 | - |
| Shapiro David | A | Jun 9, 2026 | 30,000 | - |
| George Simeon | A | Jun 9, 2026 | 30,000 | - |
| Shapiro David | A | Mar 31, 2026 | 60,000 | - |
| Shapiro David | A | Mar 31, 2026 | 7,500 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $0 | $0 |
| Operating Income | -$78.2M | -$62.4M | -$79.5M |
| Net Income | -$66.9M | -$49.6M | -$69.8M |
| Balance Sheet | |||
| Total Assets | - | $252.1M | $226.2M |
| Equity | $277.7M | $242.1M | $212.5M |
| ROE | -24.1% | -20.5% | -32.8% |
| Per Share | |||
| EPS | - | $-0.88 | $-1.22 |
| Cash Flow | |||
| Operating CF | -$58.6M | -$43.1M | -$54.4M |
| CapEx | - | $340K | $193K |
Source: XBRL data in Design Therapeutics, Inc. (DSGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate DSGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $128.0M |
| Q2 2026 | 27 | $145.5M |
| Q1 2026 | 27 | $92.7M |
| Q4 2025 | 25 | $83.9M |
| Q3 2025 | 23 | $56.3M |
| Q2 2025 | 22 | $28.8M |
| Q1 2025 | 21 | $24.7M |
| Q4 2024 | 16 | $36.3M |
- State Street Corp+937.2K (+127%)
- Invesco Ltd+131.2K (+612%)
- Vanguard Capital Management LLC+101.8K (+6%)
- AQR Capital Management+82.1K (+115%)
- Bank of America Corp+65.8K (+151%)
- Renaissance Technologies LLC−86.1K (-22%)
- Prudential Financial−72.2K (-32%)
- Morgan Stanley−70.8K (-9%)
- Goldman Sachs Group−60.0K (-9%)
- Wells Fargo & Co−18.7K (-67%)
- FMR LLC (Fidelity)−776.5K
- Millennium Management−147.7K
- Ameriprise Financial−67.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 185 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DSGN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| SC 13G | Jun 9, 2026 | - | - | |
| 8-K | May 18, 2026 | - | Analysis | |
| 8-K | Apr 28, 2026 | - | Analysis | - |
| 10-Q | Apr 28, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 1, 2026 | - | - | - |
| 4 | Apr 1, 2026 | - | - | - |
| 10-K | Mar 9, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 9, 2026 | - | Analysis | - |
| 8-K | Jan 30, 2026 | - | - | |
| 4 | Jan 5, 2026 | - | - | |
| 4 | Jan 5, 2026 | - | - | |
| 4 | Jan 5, 2026 | - | - | |
| 4 | Jan 5, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
DSGN SEC filings: frequently asked questions
Which institutions hold DSGN stock?
As of September 30, 2026, the largest Design Therapeutics, Inc. (DSGN) holders among the 13F filers tracked by SignalX were BlackRock ($34.1 million), State Street Corp ($21.0 million), Vanguard Capital Management LLC ($21.0 million), Dimensional Fund Advisors ($9.1 million), Morgan Stanley ($8.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was DSGN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Design Therapeutics, Inc. (DSGN) reported revenue of $0 and a net loss of $69.8 million. Diluted EPS was -$1.22. The figures come from the XBRL data in the 10-K.
What did DSGN report in its latest 8-K?
Design Therapeutics, Inc. (DSGN) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Design Therapeutics’ financial results for the three and nine months ended September 30, 2026.
What are the latest DSGN SEC filings?
Design Therapeutics, Inc. (DSGN) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on June 11, 2026.
What is DSGN's SEC CIK number?
Design Therapeutics, Inc. (DSGN)'s SEC Central Index Key (CIK) is 1807120. EDGAR lists every DSGN filing under that number.
Ask anything about DSGN
The research agent reads DSGN's filings, financials, insider trades and 13F holders, then answers with sources.